生殖激素和蛋白质检测市场：市场规模（按细分市场）、份额、监管、报销、预测（~2033）

生殖激素和蛋白质测试包括抗苗勒氏管激素(AMH) 实验室测试、雌二醇实验室测试、黄体酮实验室测试、硫酸脱氢表雄酮(DHEAS) 实验室测试、催乳素实验室测试、睪固酮实验室测试、黄体生成素实验室测试(LH)实验室测试、卵泡刺激素 (FSH) 实验室测试等。

生殖激素和蛋白质测试用于评估男性和/或女性的生育能力，包括促性腺激素低下性腺功能减退症、高催乳素血症、纤毛功能障碍、囊性纤维化，以及与某些疾病相关的疾病，例如沙眼衣原体和淋病奈瑟菌等性传染病。

本报告深入探讨了全球生殖激素和蛋白质检测市场，包括竞争格局、SWOT 分析、到 2033 年的市场预测、COVID-19 的影响以及区域和国家趋势。

目录

目前上市的生殖激素及蛋白质测试及竞争格局

• 对主要产业趋势的见解
• 生殖激素和蛋白质检测按细分市场划分的市场总收入以及 2015-2033 年市场前景
• 有关数量、平均售价和市场价值的详细数据

全球、区域与国家见解

• 生殖激素和蛋白质检测市场的SWOT分析
• 生殖激素和蛋白质检测市场的竞争动态洞察和趋势
• 各国医疗保健系统概览
• 按国家/地区划分的报销政策
• 各国医疗科技的监管状况

Abstract

Reproductive Hormones and Proteins Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Reproductive Hormones and Proteins tests market for the year 2020 and beyond. The Reproductive Hormones and Proteins tests include

Anti-Mullerian Hormone (AMH) lab Test, Estradiol lab Test, Progesterone lab Test, Dehydroepiandrosterone Sulphate (DHEAS) lab Test, Prolactin lab Test, Testosterone lab Test, Luteinizing Hormone (LH) lab Test, and Follicle-Stimulating Hormone (FSH) lab Test.

Reproductive Hormones and Proteins tests are performed to evaluate fertility in men and/or women and is associated with specific diseases such as hypogonadotropic hypogonadism, hyperprolactinemia, ciliary function disorders, cystic fibrosis, and sexually transmitted infections such as Chlamydia trachomatis and Neisseria gonorrhoeae.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Reproductive Hormones and Proteins Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Reproductive Hormones and Proteins Tests market revenue by segment and market outlooks from 2015- 2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Reproductive Hormones and Proteins Tests market.
• Competitive dynamics insights and trends provided for Reproductive Hormones and Proteins Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Danaher Corp, Abbott Laboratories, Siemens AG, Quidelortho Corp, F. Hoffmann-La Roche Ltd, Tosoh Corp, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Reproductive Hormones and Proteins Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Reproductive Hormones and Proteins Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Reproductive Hormones and Proteins Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Reproductive Hormones and Proteins Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Reproductive Hormones and Proteins Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable